Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2020
Price :
$35
*
At a glance
- Drugs FPF 1070 (Primary)
- Indications Vascular dementia
- Focus Therapeutic Use
- Acronyms VascDem
- Sponsors EVER Neuro Pharma
- 14 Sep 2009 Results presented at the 13th Congress of the European Federation of Neurological Sciences (EFNS).
- 04 Aug 2009 New trial record